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Malignant gliomas are the most common malignant primary brain tumors and one of the most challenging forms
of cancers to treat. Despite advances in conventional treatment, the outcome for patients remains almost
universally fatal. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal.
However, over the past decade, molecular targeted therapy has held the promise of transforming the care of
malignant glioma patients. Significant progress in understanding the molecular pathology of gliomagenesis and
maintenance of the malignant phenotypes will open opportunities to rationally develop new molecular targeted
therapy options. Recently, therapeutic strategies have focused on targeting pro-growth signaling mediated by
receptor tyrosine kinase/RAS/phosphatidylinositol 3-kinase pathway, proangiogenic pathways, and several other
vital intracellular signaling networks, such as proteasome and histone deacetylase. However, several factors such
as cross-talk between the altered pathways, intratumoral molecular heterogeneity, and therapeutic resistance of
glioma stem cells (GSCs) have limited the activity of single agents. Efforts are ongoing to study in depth the
complex molecular biology of glioma, develop novel regimens targeting GSCs, and identify biomarkers to stratify
patients with the individualized molecular targeted therapy. Here, we review the molecular alterations relevant to
the pathology of malignant glioma, review current advances in clinical targeted trials, and discuss the challenges,
controversies, and future directions of molecular targeted therapy.
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Gliomas account for about 80% of primary malignant tumors in the
central nervous system, and World Health Organization (WHO)
classification divides gliomas into four grades with increasing degreeof malignancy [1]. Each subgroup has a relatively specific prognosis
that guides the clinical management; unfortunately, anaplastic
gliomas (WHO III) and glioblastomas (GBMs, WHO IV) constitute
the majority of gliomas and are essentially incurable.E-mail: fu800da900@126.com
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Figure 1. Three core signaling pathways altered in malignant gliomas. DNA alterations and copy number changes in the RTK/RAS/
PI3K, RB, and p53 are shown. Moreover, activating genetic alterations are indicated in red, and inactivating genetic alterations are
indicated in purple. In each pathway, the altered components and the type of alteration are indicated. The types of alteration are
represented by different patterns as follows: represents mutation, represents amplification and represents homozygous
deletion, while represents gene with normal copy number. MG indicates malignant glioma; HER, human epithelial receptor;
MET, mesenchymal epithelial transition factor.
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temozolomide (TMZ) combined with radiotherapy are standard-of-
care treatment strategies for this disease. However, the malignant
behavior of these cancers with resistance to chemotherapy and
radiation results in a high recurrence rate, and thus, patients with
malignant glioma derive little benefit from standard treatments [2].
The disease ultimately follows a fatal course with the median survival
of 12 to 15 months and 2 to 5 years for patients with GBM and
anaplastic glioma, respectively [3].
To break through these challenges for malignant glioma therapy
posed by limitations in the current therapeutic strategies, novel
therapies such as molecular targeted therapy, immunotherapy, gene
therapy, stem cell–based therapies, and nanotechnology have emerged
from the interface between preclinical and clinical research [4]. Due
to the success of molecular targeted therapy in several other cancer
types such as non–small cell lung cancer [5], melanoma [6], and
chronic myelogenous leukemia [7], this therapeutic strategy holds
significant promise for the treatment of malignant glioma and has
greatly advanced over the past decade, with such molecularly targeted
therapeutics as bevacizumab, a monoclonal antibody against vascular
endothelial growth factor (VEGF), being granted approval by the US
Food and Drug Administration for treating recurrent GBM in
2009 [8–10].
However, despite increasing radiographic response and progres-
sion-free survival (PFS), bevacizumab does not benefit overall survival(OS) in either recurrent GBM or newly diagnosed GBM [11–14].
Hence, with an increasing understanding of the molecular pathology
of malignant glioma, novel signaling pathways driving gliomagenesis
and progression that are candidates to become therapeutic targets and
novel agents that may target relevant pathways more effectively are
urgently needed. Herein, we set forth the rationales for targeting
molecular pathways in malignant glioma, review current clinical trials
for these tumors, and discuss the challenges, controversies, and future
directions of molecular targeted therapy.
MultipleCoreSignalingPathways inMalignantGlioma
With high genetic and pathologic heterogeneity even in the same
tumor sample, and low prevalence of each molecular abnormality,
malignant gliomas are usually not defined by a single genetic
mutation or molecular alteration. Thus, a “single gene–based” process
of target identification and targeted therapy development is
prohibitively difficult. It will be necessary to understand the pathways
within which different genetic alterations function to drive
gliomagenesis, progression, and treatment resistance and then focus
our efforts in the development of a biologically meaningful
classification scheme for treating these tumors.
Recently, The Cancer Genome Atlas (TCGA) research network
identified three core signaling pathways underlying malignant
glioma pathogenesis: receptor tyrosine kinase (RTK)/RAS/
phosphatidylinositol 3-kinase (PI3K), p53, and retinoblastoma
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other canonical signaling pathways like proangiogenic pathway are
important for gliomagenesis and maintenance of glioma phenotypes.
RTK/RAS/PI3K Pathway
Growth factor receptors [e.g., epidermal growth factor receptor
(EGFR) and PDGF receptor A (PDGFRA)] are RTKs that are plasma
membrane–spanning proteins consisting of extracellular domains that
can be bound by the receptors' respective ligands (e.g., EGF and
PDGF) and intracellular domains associated with tyrosine kinase
activity. Activation of several RTKs is frequently found in malignant
glioma, such as EGFR gene amplification that occurs in approxi-
mately 40% of patients with GBM and PDGFRA gene amplification
that occurs in up to 16% of GBM [16,17]. Usually, RTKs are
activated through the interaction of growth factors and RTKs, but a
unique EGFR variant (EGFRvIII) shows ligand-independent
constitutive activation of the receptor. This deletion mutant is
observed in approximately 30% to 50% of EGFR-amplified gliomas
[16]. Mutated RTKs will contribute to recruitment of PI3K, RAS,
and so on, to the cell membrane to trigger signal transduction
cascades. It is thought that PI3K then initiates activation of
downstream effectors such as AKT and mammalian target of
rapamycin (mTOR) that function as central regulators of cellular
metabolism, proliferation, cell cycle control, differentiation, and
angiogenesis [18]. This activation pathway is held in check by the
phosphatase and tensin homolog (PTEN) protein inhibiting PI3K
activity. However, biallelic inactivation of the PTEN gene located on
chromosome 10q occurs in up to 40% of malignant gliomas, which
makes the PI3K/AKT pathway active constitutively [18,19].
Mutation of RAS increases the activity of the RAS–RAF–mitogen-
activated protein kinase (RAS/RAF/MAPK) pathway and results in
uncontrolled cell growth and proliferation; however, RAS mutation is
a fairly rare occurrence in malignant glioma. Mutation or
amplification of upstream RTKs and mutation or deletion of the
neurofibromin 1 gene that encodes neurofibromin functioning as a
negative regulator of RAS seem to accomplish the result of a
permanent activation of RAS, leading to proliferation, motility, and
survival [15,20]. In sum, all genetic alterations of the RTK/RAS/
PI3K pathway in GBM were confirmed by TCGA with a total
percentage up to 88% of tumors [15].
P53 Pathway
The Tumor Protein p53 (TP53) tumor suppressor gene encodes a
protein that regulates several cellular programs including the cell cycle
arrest, response of cells to DNA damage, senescence, apoptosis, and
differentiation [21,22]. When cells are under genotoxic and cytotoxic
stress, p53 functions as a transcription factor to regulate expression of
downstream effector genes to determine cell fate [23,24]. Loss of
normal TP53 function resulting from TP53/mouse double-minute 2
(MDM2)/MDM4/p14ARF alterations has been linked to clonal
expansion of glioma cells [25]. The human homolog of MDM2
inhibits p53 function, MDM4 regulates p53 activity, and p14ARF is
negatively regulated by p53 [21,24]. Of these classic pathway targets,
TCGA has demonstrated altered constituents of the pathway
including TP53 mutation or deletion (35%), MDM2 amplification
(14%),MDM4 amplification (7%), and p14ARF mutation or deletion
(49%) in GBM [15]. Notably, MDM2 amplification and TP53
mutation are alterations found in a mutually exclusive fashion, as well
as p14ARF alteration and TP53 mutation [21]. However, perhaps as aresult of its near-ubiquitous pathway inactivation, TP53 status has
not been found to display any clear relationship with treatment and
outcome in malignant glioma [22].
RB Pathway
Like TP53, RB is a tumor suppressor gene encoding the
retinoblastoma susceptibility protein 1 (RB1) that inhibits entry of
cells through G1 into the S-phase of the cell cycle [21]. When
phosphorylated by cyclin D, cyclin-dependent kinase 4 (CDK4), and
CDK6, RB1 will be inactive, thereby disinhibiting progression
through the cell cycle [25]. Thus, aberration of associated cell-cycle
regulators from genetic alteration of p16INK4a/CDK4/RB1 pathway
components leads to glioma proliferation [23]. RB1 mutation or
deletion and CDK4 amplification account for inactivation of RB1,
and cyclin-dependent kinase inhibitor 2A (CDKN2A) gene mutation or
homozygous deletion also results in loss of normal RB1 function
[15,21]. Overall, the frequency of genetic alterations in this pathway
amounts to 78% of GBMs, with CDKN2B deletion (47%),
CDKN2C deletion (2%), cyclin D2 (CCND2) amplification (2%),
CDK6 amplification (1%), RB1 mutation or deletion (11%),
CDK4 amplification (18%), and CDKN2A(p16INK4a) mutation or
homozygous deletion (52%), as reported by TCGA [15]. Among
them, CDKN2A mutation or homozygous deletion leads to loss of
p16INK4a, which is an inhibitor of CDK4, and the CDKN2A gene
encodes p16INK4a and p14ARF that exert respective functions in the
RB and p53 pathways, therefore revealing the critical importance of
the single genetic inactivation of CDKN2A for these two core
pathways in the growth of glioma [25].
Proangiogenic Pathway
For angiogenesis, several signaling pathways are theorized to
contribute to the process of vasculature development. In one model
of step-wise progression, the first step of glioma achieving its vasculature
is vascular co-option, a process by which several proangiogenic factors
such as angiopoietin-2 (ANG-2) and its receptor tyrosine kinase with
immunoglobulin-like and epidermal growth factor homology domains
2 (TIE-2) are upregulated in endothelial and tumor cells that promote
vessel disruption, and then VEGF binding to VEGF receptor (VEGFR)
activates intracellular signaling cascades transduced by RAS/MAPK and
PI3K/AKT pathways to promote migration and proliferation of
endothelial cells and stimulate formation of new blood vessels and
also induces endothelium to express integrin that mediates largely the
final stages of angiogenesis [26–29]. Activated endothelial cells also
secrete PDGF to recruit pericytes to the new vessels, stabilizing them in
a process mediated by the angiopoietin/TIE pathway [30,31].
Furthermore, several other pathways have been proposed to contribute
to the process of angiogenesis, such as erythropoietin and its receptor,
Delta-like 4 and its receptor Notch, hypoxia-induced factor-1α, basic
fibroblast growth factor, neuropilin, and stromal-derived factor 1
[25,28,32,33]. In addition, endogenous angiogenesis inhibitors such as
the soluble form of the VEGFR 1, thrombospondin-1, angiostatin,
vasculostatin, and endostatin can play important roles in the delicate
balance of angiogenic potential in tumors [29,32].
Current Standard Therapeutic Modalities
in Malignant Glioma
Radiotherapy + TMZ
Of all adjuvant therapies, radiotherapy offers relatively greater
magnitude of survival benefit, so that almost all patients with
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radiotherapy plus the chemotherapy agent TMZ, a new-generation
alkylating agent, for GBM patients has been evaluated in a
randomized phase III trial. This regimen, which has minimal
additional toxicity, was demonstrated to increase the median OS to
14.6 months and the 2-year OS to 27.2%, compared to 12.1 months
and 10.9%, respectively, in the radiotherapy alone group [35,36].
Moreover, patients with epigenetic silencing of O6-methylguanine
DNA methyltransferase (MGMT) benefitted more from TMZ
treatment [37]. On the basis of these findings, TMZ has
been incorporated into multimodal treatment strategies for
malignant gliomas.
Antiangiogenesis
Contemporary clinical studies also focus on the role of angiogenesis,
which is a hallmark of GBM. Currently, antiangiogenesis therapies
using the antibody against VEGF and the antagonists of VEGFR/
integrin are being increasingly investigated for malignant glioma.
VEGF/VEGFR. The VEGF/VEGFR system is the major and
critical regulator of angiogenesis on malignant gliomas. The level of
VEGF expression has been positively related to the tumor’s
malignancy degree. Hence, targeting VEGF/VEGFR is proposed to
be an effective means to control glioma growth [26,27,38].
Given that bevacizumab has not been demonstrated to increase OS
in GBM, investigators have shifted strategies towards combined
therapies, including bevacizumab with radiotherapy and other
chemotherapeutics. A multicenter study and a meta-analysis of
bevacizumab in combination with irinotecan in recurrent malignant
glioma only demonstrated higher PFS at 6 months (PFS-6) and
response rate and similar OS compared with bevacizumab mono-
therapy [39,40]. Similar results were also obtained from a phase II
trial, which compared the bevacizumab + TMZ + radiotherapy with
TMZ + radiotherapy for newly diagnosed GBM [41].
In addition, the clinical benefits of bevacizumab seem obvious (e.g.,
decreasing peritumoral edema, reducing amount of steroid, and
improving neurologic symptoms), but it still has not been approved
by the European Medical Agency for malignant glioma treatment [2].
Moreover, recent clinical studies have implicated that bevacizumab only
had a transient antiangiogenic antiglioma effect and made a subset of
GBM patients develop multifocal or diffuse recurrence during the
course of bevacizumab therapy. This phenomenon appears to be more
prevalent in malignant glioma patients with bevacizumab over-usage
[28,29]. Likewise, patients who have failed bevacizumab have
particularly dismal outcomes, as the median OS and PFS-6 have been
reported to be 2 to 5 months and 0% to 4%, respectively [42]. Thus,
there is a clear need for salvage therapies forGBMpatients with rebound
of intracranial edema and diffuse invasive recurrence patterns.
Notably, Aguilera et al. reported that two cases with diffuse
intrinsic pontine glioma had ongoing PFS of 37 and 47 months from
diagnosis and decreased tumor size by N65% [43] with bevacizumab
+ radiation + TMZ. Clinical trials are expected to re-evaluate response
of the therapeutic schedule in malignant gliomas based on the positive
impact of bevacizumab on survival.
Aflibercept is a novel agent that targets VEGF with a soluble decoy
VEGFR fused to an immunoglobulin constant region and also binds
placental growth factor [2]. However, a phase II trial of aflibercept
monotherapy in recurrent malignant glioma showed minimal
evidence of single-agent activity with PFS-6 of 7.7% and median
PFS of 12 weeks for GBM patients and PFS-6 of 25% and medianPFS of 24 weeks for anaplastic glioma patients [44]. Additionally,
long-term treatment with aflibercept seemed to result in acquisition
of an invasive phenotype of glioma, which seemed to coincide with
preliminary data in GBM patients treated with bevacizumab [45].
RTK inhibitors (TKIs) targeting VEGFR include cediranib,
vatalanib, pazopanib, cabozanitib, and several other multitargeted
kinase inhibitors. Recently, a phase II study of cediranib [inhibitor of
VEGFR, PDGFR, fibroblast growth factor receptor 1 (FGFR1), and
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
(c-KIT)] monotherapy in patients with recurrent GBM showed that
PFS-6 was 25.8% and the radiographic partial responses were 56.7%
by magnetic resonance imaging with three-dimensional measure-
ments and had a steroid-sparing effect [46]. Concurrently, results
indicated that cediranib could normalize tumor vessels, reduce
cellularity in tumor central area, reduce peritumor edema, and inhibit
a second wave of angiogenesis [47,48], which presumes that vascular
normalization can potentially be beneficial for chemotherapy delivery
and provide a rationale for combined therapy. Another study
demonstrated that cediranib enhanced the effectiveness of TMZ in
both wild-type EGFR and EGFRvIII expressing glioma cells [49].
Notably, the structural and functional normalization of tumor vessels
induced by cediranib also improved tumor blood perfusion for 1
month and was associated with longer survival in GBM patients [50].
These results implicate that anti-VEGFR may improve glioma patient
survival by feeding the cancer with normalized vasculature and
improving chemotherapy delivery rather than starve the tumor
through elimination or reduction of tumor vasculature.
Concomitant and adjuvant TMZ and radiotherapy with vatalanib
(inhibitor of VEGFR, PDGFR, and c-KIT) was evaluated in newly
diagnosed GBM patients in phase I/II trials. The result showed that
the median OS and median PFS were 17.3 and 6.8 months,
respectively [51]. Similar to vatalanib, pazopanib (inhibitor of
VEGFR, PDGFR, and c-KIT) did not provide any significant
benefit to recurrent GBM patients in a phase II trial as the median
OS, median PFS, and PFS-6 were 35 weeks, 12 weeks, and 3%,
respectively [52].
Cabozanitib also has potent activity against MET, which is
important in both angiogenesis and invasion of glioma [53]. In a
phase II study, cabozanitib alone achieved modest but promising PFS
with a high response rate (21-30%) in recurrent GBM patients
without prior antiangiogenic agents [54,55]. Moreover, recent
preclinical data showed significant increase in OS of GBM xenografts
[56]. However, GBM would ultimately escape from cabozanitib by
diffuse infiltration and blood-brain barrier (BBB) restoration. Thus,
cabozanitib delivery was limited [56]. Further trials of cabozanitib are
encouraged based on the promising results but not ignoring potential
shortcomings of this drug.
Integrin. Integrins are a large family of cell surface adhesion
molecules, which mediates the adhesion between cells and cell-
extracellular matrix. Recently, they have also been identified as an
important factor for glioma-associated angiogenesis. So far, two
isoforms of integrins (ανβ3 and ανβ5) have been identified as having
high expression levels in both glioma cells and the endothelial lining
of blood vessels and mediating glioma invasion and migration [57].
Cilengitide can selectively block activation of ανβ3 and ανβ5 and
exert a bimodal phenotypic antitumor effect by inhibiting angiogen-
esis and glioma cell invasion in vivo[58,59]. Although monotherapy
had only limited effect in GBM, cilengitide with standard radiation
and TMZ appeared to improve PFS and OS in newly diagnosed
Figure 2.Molecular targets ingliomacells (A) andglioma-associatedendothelial cells (B) anddesigned intervention inmolecular targeted therapies
formalignant glioma.Growth factor receptors, glioma-associated transmembrane proteins, and their downstream intracellular signaling pathways
are commonly altered ingliomaandhavebeen implicated ingliomagenesis. Severalmoleculesof themhavebeenexplored as the targets to inhibit
gliomagrowth and angiogenesis. GF indicates growth factor; ECM, extracellularmatrix; TF, transcription factor; NICD,Notch intracellular domain.
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significant activity of cilengitide plus standard of care was also seen in
a randomized phase II study, demonstrating median survival of 30
and 17.4 months in methylated and unmethylated MGMT newly
diagnosed GBM patients, respectively [61].
Additionally, high-dose cilengitide seemed to have more benefits
[61]. Promising results in these trials resulted in a broader interest in
cilengitide for glioma therapy. However, no significant improved
median OS was found in a recent study evaluating cilengitide
combined with standard treatment for patients with newly diagnosed
GBM with a methylated MGMT promoter. The cilengitide-treated
group had a median OS of 26.3 months, while that of the control
group was 26.3 months [62]. Subsequently, efficacy and safety of
cilengitide in conjunction with radiotherapy and chemotherapy are
currently being assessed in a randomized phase II study for newly
diagnosed GBM patients with an unmethylated MGMT gene
promoter (NCT00813943).
Moreover, a case report suggested that cilengitide had significant
antitumor activity in treating bevacizumab-refractory high-grade glioma
[63]. This finding might be due to the upregulated integrin signaling in
bevacizumab-treated glioma. Further clinical trials could evaluate the
antitumor effect of combined VEGF and integrins in glioma patients,
especially for those where bevacizumab was ineffective.
Thalidomide can also interfere with the expression of ανβ3 and
ανβ5. Moreover, it plays an important role in inhibiting basic
fibroblast growth factor and VEGF-mediated angiogenesis [64,65].
However, a few phase II trials of thalidomide observed negative results
in either monotherapy or in combination with TMZ, procarbazine,
or irinotecan in recurrent high-grade gliomas [66–69].
Ongoing Experimental Options for Molecular
Targeted Therapy
The loss of p53 and RB tumor suppressor pathways accompanies
pro-growth signaling RTK/RAS/PI3K pathway to induce glioma
formation [2]. The genetically engineered mouse models have
definitively implicated this combination [70]. Specific targeting of
these signaling pathways is therefore a rational treatment strategy for
molecular therapy of glioma. However, the p53 and RB pathways are
difficult to target. In contrast, targeting gain-of-function molecules is
relatively easier. Current efforts are mainly focused on amplified,
mutated, and/or overexpressed effectors of the RTK/RAS/PI3K
pathway and other novel targets such as proteasome and so on. The
pro-growth signaling pathways and their designed intervention are
shown in Figure 2, A and B.Growth Factor Receptors
Growth factor receptors are critical regulatory proteins in signaling
networks of malignant glioma. Novel agents designed to target specific
proteins such as EGFR and PDGFR are currently in clinical trials.
EGFR. EGFR activated by EGF or transforming growth factor α
and the constitutively activated variant EGFRvIII promote growth
signal transduction through activating several downstream signaling
pathways and contribute to tumor progression and poor prognosis
[71]. EGFR- and/or EGFRvIII-targeted therapies are suggested to
produce anticancer effect and have been extensively evaluated
preclinically and clinically in malignant gliomas.
Recently, a phase II clinical trial of an EGFR monoclonal antibody
cetuximab in patients with recurrent GBM with EGFR amplification
showed that patients with positive EGFRvIII had a worse survivalcompared with negative ones (i.e., median PFS: 1.63 vs 3.03 months;
median OS: 3.27 vs 5.57 months) [72]. Another phase II
monotherapy trial in patients with recurrent high-grade gliomas
demonstrated limited activity of cetuximab (PFS-6 of 9.2%; median
OS of 5 months) and failed to find significant correlation between
response or survival and EGFR amplification [73]. In short,
cetuximab monotherapy has not yet been demonstrated to have
clinical benefits, while the outcome of glioma patients treated with
cetuximab seems to be associated with EGFRvIII but not
amplification alone. Thus, future investigations of EGFR status in
EGFR-targeted therapies are indicated.
Gefitinib’s effect in newly diagnosed GBM patients was also
neither affected by EGFR amplification nor mutation (i.e.,
EGFRvIII) in a phase II trial [74]. The post-radiation gefitinib
application did not improve survival and neither OS at 1 year nor PFS
at 1 year (PFS-1) was statistically different compared with historical
control data from the North Central Cancer Treatment Group
(OS-1: 54.2% vs 48.9%; PFS-1: 16.7% vs 30.3%) [74]. Further-
more, addition of gefitinib to radiation demonstrated little
improvement compared with radiotherapy alone in terms of median
survival in patients with newly diagnosed GBM [75].
Another TKI erlotinib whose activity was also not associated with
EGFR amplification or EGFRvIII status had an unacceptable toxicity
but did not have any clinical benefit as a monotherapy or in
combination with radiotherapy and TMZ in several phase II trials of
malignant glioma [76–78]. Lapatinib suffered the same fate as
erlotinib [79].
With respect to the failures of reversible EGFR inhibitors, which
are susceptible to acquired resistance in EGFR-targeted therapies,
other current trials in patients with malignant glioma are focusing on
irreversible EGFR inhibitors such as humanized monoclonal
an t ibody n imotuzumab [80 ,81 ] and RTK a f a t in ib
(NCT00727506; NCT00977431). Nimotuzumab has the advantage
of preferentially binding to areas with a high density of EGFR [82]. A
randomly controlled trial revealed that nimotuzumab had better
activity than radiotherapy and chemotherapy alone, as improved
treatment efficacy and prolonged survival were observed in malignant
glioma patients with nimotuzumab [median OS: 16.5 vs 10.5
months (control groups)] [80]. A 5-year institutional experience also
demonstrated evident clinical benefit in children with high-grade
glioma treated by regimens containing prolonged administration of
nimotuzumab (median OS: 32.66 months; OS-2: 54.2%) [81]. In
combination, nimotuzumab shows a potential antiglioma activity,
which may be worth further investigation. Meanwhile, two ongoing
clinical trials are evaluating the safety and efficacy of afatinib either in
monotherapy or in combination with radio-chemotherapy in
patients with recurrent or newly diagnosed malignant glioma
(NCT00727506; NCT00977431).
Given that EGFRvIII overexpression concurrent with EGFR
amplification is a hallmark for high invasion and resistance to therapy
and that EGFRvIII-positive glioma cells can release microvesicles
containing EGFRvIII to surround EGFRvIII-negative glioma cells
and lead to transfer of oncogenic activity and enhanced tumorige-
nicity, EGFRvIII-targeted therapy may have more potential to be
effective [83,84].
These agents mentioned previously mainly target wild-type EGFR.
Only a limited amount of EGFRvIII-specific or preferential agents are
in development, such as monoclonal antibodies (L8A4 and mAb806)
and TKIs (AG1478 and NSC154829) [85]. Several preclinical
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AG1478 in glioma cells and models [86–89]. AG1478 can also
enhance the antitumor efficacy of mAb806 and cytotoxic agents,
which indicates the promising future of AG1478 in combination with
application prospects [89]. Another novel molecule NSC154829 was
shown to selectively inhibit EGFRvIII-expressing GBM cell growth
and increase apoptosis [90]. Further testing is under way.
Unfortunately, few clinical trials have been carried out in glioma
patients with these EGFRvIII-specific agents. Only a phase I trial has
been published in which patients with several human cancer types
received mAb806 monotherapy and only one of the participants was a
glioma patient [91]. This area needs further exploration.
PDGFR. PDGFRs (α and β) interact with different PDGF
subunits (-A,-B and -C) to form an autocrine and paracrine
stimulation loop between cancer cells and tumor blood vessels and
are therefore important for tumor growth and angiogenesis [17,92].
Blocking PDGFR can inhibit PI3K/mTOR and RAS/MAPK
pathways and has an antitumor activity. Thus far, several TKIs have
been evaluated in preclinical or clinical studies in malignant glioma.
Imatinib is a TKI of PDGFR, c-KIT, and BCR-ABL. Imatinib can
enhance chemosensitivity and its response is associated with increased
PDGFRα expression [93,94]. However, a recent study revealed that
imatinib had no significant inhibitory effects against malignant
glioma and cautioned on its use [95]. Consistent with this finding, a
few phase II studies of imatinib plus hydroxyurea demonstrated
negligible antitumor activity in patients with either recurrent/
progressive low-grade glioma or recurrent GBM. The radiographic
response rates were 0 and 3.4%, respectively [93,96].
Dasatinib, an ATP-competitive inhibitor of PDGFR, c-KIT,
BCR-ABL, and SRC [97], is undergoing evaluation as a monotherapy
in a phase II trial for patients with recurrent GBM (NCT00423735).
However, dasatinib in combination with lomustine (CCNU) in
patients with recurrent GBM showed no significant effect in a phase I/II
trial, of which the median PFS was 1.35 months and PFS-6 was only
7.7% [98].
The study of a second-generation PDGFR inhibitor tandutinib is
also ongoing (NCT00379080). Notably, the adverse effect on
neuromuscular junction may limit anti-PDGFR’s usage [99].
Intracellular Signaling Pathways
Several intracellular pathways mediate signals transduced by
upstream RTKs and promote diverse cellular effects such as
proliferation, survival, and angiogenesis. Targeting specific signaling
mediators will block signal transduction and may lead to inhibition of
glioma growth.
PI3K/AKT/mTOR Pathway. Activated by EGFR, EGFRvIII,
PDGFR, and RAS pathways, the PI3K/AKT/mTOR pathway has
emerged as a central player in glioma pathogenesis by promoting
growth and survival [71].
A preclinical study showed that inhibiting PI3K by LY294002
could decrease TMZ resistance by promoting p-AKT and Bcl-2 and
enhance cytotoxicity of TMZ by downregulating PI3K/AKT
pathway in glioma. LY294002 plus TMZ significantly suppressed
proliferation of glioma cells compared with monotherapy of either
drug [100]. Furthermore, inhibition of the PI3K/AKT signaling
pathway also radiosensitizes cancer cells and delays DNA repair after
irradiation [101]. However, radiation-induced up-regulation of
telomerase (a ribonucleoprotein complex that elongates telomeric
DNA and regulates the cellular immortalization of cancers) activitycould escape PI3K inhibition in LY294002-treated glioma cells,
which suggests that specific suppression of PI3K when combined with
radiation may be optimized by additional treatments inhibiting
telomerase in malignant glioma [101,102].
An AKT-targeted agent perifosine can also cooperate with TMZ to
exert strong antitumor activity. However, it failed to enhance
radiosensitivity in glioma cells and models [103–105].
In terms of mTOR inhibitors, previous preclinical studies have
revealed that PTEN-deficient gliomas were more sensitive to mTOR
inhibition [71]. Due to the high frequency ofPTEN gene abnormality in
malignant glioma, trials of mTOR inhibitors are very promising.
However, recently, aGBMxenograft test panel suggested no relationship
between loss of PTEN function and responsiveness tomTOR inhibitors,
which is consistent with the data from a phase I trial of patients with
recurrent PTEN-deficient GBM treated with rapamycin that observed
substantially variable mTOR inhibition [106,107].
Several rapamycin analogs are undergoing evaluation, such as
temsirolimus, everolimus, and deforolimus. Although trials have
shown that these agents were well tolerated by patients, monother-
apies have generally failed without major clinical benefit seen in
malignant glioma patients including children with high-grade glioma
[108–111]. For example, temsirolimus only produced minimal
clinical activity with low PFS-6 (7.8%) and median OS (4.4 months)
in recurrent GBM patients [112]. Preclinical trials demonstrated that
mTOR inhibitors could also sensitize tumor cells to radiotherapy or
TMZ in combined therapies. One recent study demonstrated that
temsirolimus plus radiotherapy prolonged survival of glioma-bearing
mice [113]. However, the combination of temsirolimus with
radiotherapy and TMZ might increase infections in patients with
newly diagnosed GBM due to the suppression of several immune
system components as reported by a North Central Cancer
Treatment Group phase I trial, and no definitive conclusions were
drawn regarding efficacy of the regime because of the limited number
of patients and short follow-up [114]. During a median follow-up of
8.4 months, everolimus and TMZ in combination with radiation
resulted in only one partial response in 18 patients with newly
diagnosed GBM [115]. A larger sample pool and a longer follow-up
are needed to further evaluate the effect of temsirolimus.
Recent studies have indicated that the limited clinical activity of
mTOR inhibitors may result from the mTOR-p70S6K-PI3K
feedback loop. This resulted in the development of inhibitors dually
targeting PI3K and mTOR, such as NVP-BEZ235 and XL765 [116].
In in vitro and in vivo studies, NVP-BE235 significantly prolonged
the survival of tumor-bearing animals and displayed multifaceted
antiglioma activity such as down-regulation of VEGF, radiosensitiza-
tion of glioma cells and glioma stem cells (GSCs), and autophagy
[117–119]. In addition, XL765 showed a trend toward improvement
in survival in GBM xenografts when combined with TMZ [120].
These results suggest that further investigation of these drugs may be
warranted in glioma clinical trials.
RAS/RAF/MAPK Pathway. RAS proteins are recruited to the
inner plasma membrane by its upstream growth factor receptors
[121]. When bound to the membrane, RAS undergoes posttransla-
tional modification by farnesyl transferase (FT) and becomes ready for
signal transmission within the cell [20]. Downstream of RAS lies the
RAF/MEK/MAPK pathway. Retrospective studies have reported that
activated MAPK predicts radiotherapy resistance and poor outcomes
in patients with GBM [122]. Thus, targeting RAS signal pathway is a
rational treatment strategy.
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pathway but also partially block RhoB and the PI3K/AKT pathway
[123]. Moreover, the FTI lonafarnib was found to have a significant
inhibitory activity and improve effectiveness of TMZ and radiation in
malignant glioma cells [124]. Recently, a phase I trial of lonafarnib +
TMZ combination in glioma patients reported median OS and
median PFS of 14.3 and 4.5 months, respectively. The phase II trials
are expected [125].
Simultaneously, another FTI tipifarnib in monotherapy demon-
strated discouraging results with a median OS of 7.7 months in a
phase II trial for newly diagnosed GBM patients. The study was
stopped due to no tumor response and progression of 48% patients
[126]. Whereas tipifarnib plus TMZ and radiation was well tolerated
in patients with newly diagnosed GBM as shown by a phase I trial,
phase II studies are needed to evaluate the therapeutic strategy [127].
Other Molecular Targets in Development
Proteasome. Imbalance of the ubiquitin-proteasome degradation
system would lead to cancer cells escaping cell cycle control,
inhibition of chemotherapy-induced apoptosis, and development of
drug resistance. Thus, targeting this pathway is a viable option
[128,129]. Bortezomib is a proteasome inhibitor that can cause
apoptosis and cell cycle arrest in human GBM cells [130]. A phase I
trial showed that bortezomib had limited improvement in response
rate (3%) and survival time (PFS-6 of 15%; median OS of 6 months)
in patients with recurrent high-grade gliomas, and its maximum
tolerated dose was affected by enzyme-inducing antiepileptic drugs
[131]. Another phase I study using bortezomib, concurrent TMZ,
and radiotherapy appeared to be effective in high-grade glioma
patients when compared to historical norms: newly diagnosed
high-grade glioma patients seemed to have a slightly longer median
OS than that of historical controls (16.9 months vs 14.4 months)
[132]. Further formal phase II studies are needed to evaluate the
potential effect of bortezomib in combination with standard of care.
Histone Deacetylase. Histone deacetylases (HDACs) and histone
acetyltransferases play opposite roles in the regulation of acetylation of
histone and non-histone substrates including tumor suppressor
proteins and oncogenes [133,134]. Inhibition of HDAC’s function
can activate silent tumor suppressor genes and result in cell cycle
arrest, induce differentiation, and promote apoptosis in cancer cells
[135]. Vorinostat and romidepsin are two HDAC inhibitors.
Vorinostat showed modest single-agent activity in treating patients
with recurrent GBM, with a median OS of 5.7 months and PFS-6 of
15.2% in a phase I/II trial. Romidepsin was also not effective in
another trial where median OS for recurrent GBM was only 34 weeks
and median PFS was 8 weeks [136,137]. Nevertheless, preclinical
studies have demonstrated that HDAC inhibitors that help unravel
the DNA are effective radiosensitizers in cancers including GBM
[134]. Combination regimens are under investigation, such as
vorinostat with radiotherapy and TMZ in newly diagnosed GBM
and vorinostat combined with radiation therapy in recurrent glioma
[138] (NCT00731731; NCT01378481).
Recently, a study showed that the HDAC inhibitory properties of
valproic acid, which is a known antiepileptic agent and radiotherapy
sensitizer, could mediate the prolonged survival derived from
radio-chemotherapy seen in GBM patients [139]. A phase II trial
of valproic in combination with TMZ and radiotherapy for GBM
patients is ongoing (NCT00302159). Notably, a case of GBM
receiving an experimental protocol of concurrent valproic acid, TMZ,and radiation has lived for 3.5 years since the initial GBM diagnosis
with no disease progression [134].Issues with Resistance and Multiple Targets in
Therapy and Strategies to Overcome These Barriers
Multiple Targets in Therapy
Reviewing these clinical trials, various molecularly targeted
single-agent therapies have failed to demonstrate a significantly better
survival compared with current standard treatment regimens. These
disappointing results may be due to several factors, including the
presence of multiply mutated tyrosine kinases, redundant signaling
pathways, and pathway co-activation in most malignant gliomas.
Thus, targeting multiple signaling pathways simultaneously by
multitargeted kinase inhibitors or combinations of targeted agents
may improve outcomes.
Multitargeted Kinase Inhibitor. Multitargeted kinase inhibitors
are more convenient to administer and avoid the potential pitfalls of
drug-drug interactions and synergistic toxicity. Antiangiogenesis
drugs such as cediranib, pazopanib, vatalanib, and cabozanitib have
inhibitory activities against multiple kinases. Several other multitar-
geted kinase inhibitors such as the dual EGFR and VEGFR inhibitors
vandetanib and AEE788, VEGFR, PDGFR, c-KIT and FLT-3
inhibitor sunitinib, and RAF, VEGFR, PDGFR, c-KIT, and FLT-3
inhibitor sorafenib have been under development as well [25,140].
Recently, vandetanib monotherapy demonstrated insignificant activ-
ity in unselected patients with recurrent malignant glioma in a phase
I/II trial, whereas combined therapy of vandetanib and TMZ could
provide a marked 94% tumor volume reduction in a glioma xenograft
model. Further studies of combination treatment are warranted based
on the results of xenograft and several other phase I trials [141–144].
For other agents, monotherapies of AEE788 and sunitinib did not
demonstrate significant antitumor activity in patients with recurrent
malignant gliomas in respective clinical trial. Neither did combined
therapies of sorafenib plus TMZ and sunitinib plus irinotecan.
Notably, AEE788 had unacceptable toxicity and a clinical trial was
discontinued prematurely [145–148]. Although a phase I trial of
sorafenib with traditional treatment for both primary and recurrent
high-grade gliomas showed impressive results that cell viability was
significantly reduced, and the median OS of the entire population was
18 months, a phase II trial of the regimen was recommended [149].
In all, the studies of multitargeted kinase inhibitors for treatment of
malignant glioma patients are at the initial stage. However, there are
still some factors, such as modest benefit and potential dangers of
synergistic or additive toxicities, which need further investigation.
Combination of Targeted Agents. Combined therapy of kinase
inhibitors can target the same kinase or one pathway with synergistic
effect and strengthened inhibition. In addition, it can target different
kinases and pathways to create multiple antitumor effects and prevent
drug resistance. Recently, targeting EGFR and downstream effectors
in PI3K/AKT/mTOR pathways has been attractive, for they are
complementary targets and among the most commonly aberrant
molecules in malignant gliomas [3]. For example, gefitinib in
combination with everolimus and erlotinib in combination with
sirolimus both target EGFR and mTOR. However, phase II trials of
the two combinations had negligible activity among unselected
recurrent GBM patients with the median OS being 5.8 and
8.5 months, respectively [150,151]. Phase I studies of gefitinib plus
sirolimus and AEE788 plus everolimus in recurrent GBM patients
Figure 3. GSC-related signaling pathways represent potential targets for novel treatment strategies. Notch, SHH, and Wnt/β-catenin
pathways are altered in malignant glioma and have been shown to regulate GSC function. Constituents of these pathways are potential
targets for molecular targeted therapies. NICD indicates Notch intracellular domain; LRP, lipoprotein receptor–related protein; TF,
transcription factor.
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moderate schedule. However, for AEE788 plus everolimus, a dose
increase of AEE788 to 200 mg/day and everolimus to 5 mg quaque
omni die (qod) caused significant thrombocytopenia, suggesting
pharmacokinetic drug interaction [152,153]. Other studies have
found that mTOR inhibition was associated with increasing MAPK
signaling [154]; therefore, approaches targeting cross-talk of the two
pathways may be potentially beneficial based on significant data in
PDGF-driven GBM mice treated with perifosine and temsirolimus
[155]. A phase I/II trial of the combined therapy in recurrent or
progressive malignant glioma is ongoing (NCT01051557).
Other novel combination therapies are investigated in different
phase trials. Some have been shown limited effectiveness, including
dasatinib plus erlotinib [156], pazopanib plus lapatinib [157], and
vorinostat plus bortezomib [158] in recurrent malignant gliomas,
while some others are awaiting safety information in phase I trials in
recurrent high-grade glioma, such as bevacizumab in combination
with panobinostat [158] and vorinostat combined with bevacizumab
and irinotecan [159]. Notably, the combination of cetuximab and
bevacizumab in a third-line setting was reported to be successful in a
case of relapsed brainstem GBM who achieved a complete radiologic
response and a PFS of 20 months [160]. The proposal that the two
antibodies exert multifaceted effects mainly in GSCs still needs to be
verified, while future research of the combined therapy in this type of
difficult clinical situation may be warranted.Potential Targets in GSCs
Traditional therapies and most of the paradigms discussed above
may have limited antiglioma activities, because they may only target
proliferating non-tumorigenic cells in malignant glioma. Recently,
GSCs, which have the ability of self-renewal and multilineage
differentiation, have been considered to be the cellular origin of
glioma and account for chemotherapy and radiotherapy resistance,
angiogenesis, invasion, and recurrence [3,25]. Moreover, different
types of GSCs can coexist in one GBM, contributing to cellular
heterogeneity, which is another main reason resulting in failure of
molecularly targeted therapies [161]. Thus, strategies targeting GSCs
are urgently needed. Several signaling pathways, such as the Notch,
Hedgehog, and Wnt pathways, are essential for function and
phenotype maintenance in GSCs [25] and therefore represent novel
molecular targets (as shown in Figure 3).
Notch Pathway. Notch receptors activate notch signaling by
binding to transmembrane ligands such as Delta-like 4 by cell-to-cell
contact [162]. When activated, Notch is sequentially cleaved and
releases its intracellular domain into the nucleus to trigger
notch-dependent transcription. This requires the γ-secretase activity
of a multiprotein complex [163]. Elevated notch signaling is a
contributing factor in glioma angiogenesis and the signaling has been
shown to regulate stem cell maintenance, proliferation, and multi-
potency [164]. In addition, it plays a vital role in regulation of
radioresistance and DNA damage response pathway in GSCs [165].







RR Median OS Median PFS PFS-6 (%) Reference
VEGF/VEGFR-targeted
agents
Bevacizumab VEGF Bevacizumab +
irinotecan
Recurrent MG II Grade III 22, IV 93 39.1% ORR Grade III 9 m,
IV 8 m
Grade III 6




ND GBM II 70 19.6 m 13.6 m 88 [41]
















ND GBM I/II 19 17.3 m 6.8 m 63.2 [51]
Pazopanib VEGFR, PDGFR,
c-KIT
Monotherapy Recurrent GBM II 35 2 PR 35 w 12 w 3 [52]
Integrin-targeted agents
Cilengitide ανβ3/ανβ5 integrin Ci lengi t ide +
TMZ + RT
ND GBM I/IIa 52 16.1 m 8 m 69 [60]
Ci lengi t ide +
TMZ + RT
ND GBM II 112 19.7 m 9.97 m [61]
Thalidomide ανβ3/ανβ5 integrin Thalidomide +
procarbazine
Recurrent MG II 18 0 6.4 m [68]
Thalidomide +
irinotecan
Recurrent AG II 39 2 CR, 2 PR 72 w 13 w 36 [69]
EGFR-targeted inhibitors
Cetuximab EGFR Monotherapy Recurrent GBM II 35 3.97 m 1.63 m [72]
Monotherapy Recurrent HGG II 55 5.5% PR 5.0 m 7.3 [73]
Gefitinib EGFR Monotherapy ND GBM II 96 12 m [74]
Gefitinib + RT ND GBM II 147 11.1 m 4.9 m 40 [75]
Erlotinib EGFR Erlotinib + TMZ
+ RT
ND GBM II 27 8.6 m 2.8 m 30 [77]
Monotherapy Recurrent
GBM/AA
I/II 11 0 6.9 m 1.9 m 20 [78]
Lapatinib EGFR, HER2 Monotherapy Recurrent GBM I/II 17 0 [79]
Nimotuzumab EGFR Nimotuzumab +
TMZ + RT
Grade III to IV
glioma







Recurrent GBM II 231 3.4% ORR 26.0 w 10.6 [93]
Imatinib +
hydroxyurea
Recurrent LGG II 64 0 11 m [96]




Recurrent GBM I/II 26 1.35m 7.7 [98]
PI3K/AKT/
mTOR-targeted inhibitors
Temsirolimus mTOR Monotherapy Recurrent GBM II 65 4.4 m 7.8 [112]
Temsirolimus +
TMZ + RT
ND GBM I 25 0 [114]
Everolimus mTOR Everol imus +
TMZ + RT
ND GBM I 18 1PR [115]
RAS/RAF/
MAPK-targeted inhibitors
Lonafarnib RAS (FT) Lona fa rn ib +
TMZ
MG I 36 6% PR 14.3 m 4.5 m 41.7 [125]
Tipifarnib RAS (FT) Monotherapy ND GBM II 28 0 7.7 m [126]
Other inhibitors
Bortezomib Proteasome Monotherapy Recurrent MG I 66 3% PR 6.0 m 2.1 m 15 [131]
Bortezomib +
TMZ + RT
HGG I 23 0 15.0 m 52 [132]
Vorinostat HDAC Monotherapy Recurrent GBM II 66 2 ORR 5.7 m 15.2 [136]
Romidepsin HDAC Monotherapy Recurrent MG I/II GBM 35, AG 5 GBM 0, AG 0 GBM 34 w,
AG 36 w
GBM 8 w GBM 3, AG
0
[137]




GBM6 . 5 ,
AG 7
[141]
AEE788 EGFR, VEGFR Monotherapy Recurrent GBM I 64 0 1.6-2.7 m [145]
Sunitinib PDGFR, VEGFR,
c-KIT














HGG I 18 1 CR, 4 PR 18 m [149]
RR, response rate; CR, complete response; PR, partial response; ORR, objective/overall response rate = CR + PR; SD, stable disease; TTP, time to progression; m, months; w, weeks; d, days; NG GBM,
newly diagnosed GBM; HGG, high-grade glioma; AA, anaplastic astrocytoma; AG, anaplastic glioma; MG, malignant glioma; HER, human epithelial factor receptor; RT, radiotherapy.
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γ-secretase represents a potential therapeutic strategy. In vitro and
in vivo experiments have demonstrated that γ-secretase inhibitors
negatively regulate GBM clonogenicity and positively prolong
survival [166]. RO4929097 is an inhibitor of γ-secretase whose
clinical trials are under way as monotherapy in patients with recurrent
malignant gliomas and in combined therapy with TMZ and radiation
in patients with newly diagnosed GBM in phase I and II trials
(NCT01269411, NCT01122901, and NCT01119599).
Sonic Hedgehog Pathway. Sonic hedgehog (SHH) binding to
transmembrane receptors protein patched homolog and membrane
protein smoothened homolog results in activation of Gli transcription
factors that are then transferred into the nucleus to modulate
expression of target genes that are essential for GSC self-renewal and
survival [25,163]. Inhibiting SHH pathway may be an effective
therapy to prevent malignant gliomas. An SHH inhibitor
N-[(1E)-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4yl)methylidene]-4-
(phenylmethyl)-1-piperazinamine (SANT-1) has been shown to
reduce GSC proliferation, and a RAS/nuclear factor of kappa light
polypeptide gene enhancer in B-cells (NF-κB) guggulsterone could
sensitize GBM cells to SANT-1–induced apoptosis [167]. Another
SHH inhibitor cyclopamine reduced the number of GSCs and
suppressed glioma growth in vivo and showed synergistic effects with
TMZ [168]. Clinical trials with the smoothened homolog inhibitor
vismodegib revealed encouraging antitumor efficiency and safety in
medulloblastoma [169], while a phase II trial of vismodegib in
treating patients with recurrent GBM is ongoing (NCT00980343).
Wnt/β-Catenin Pathway. Wnt/β-catenin signaling is the canon-
ical Wnt pathway that is responsible for the regulation of stem cell
self-renewal in the developing brain [170]. Due to the similarities of
pathways regulating in normal stem cells and cancer stem cells, Wnt/
β-catenin signaling is regarded to be involved in the regulation of
cancer stem cells including GSCs, which has a vital role to play in
malignant transformation and tumor progression in gliomas
[171,172]. Although the function of this signaling pathway in
GSCs has not been extensively elucidated, blockade of Wnt pathway
may effectively target GSCs. Several molecular targeted agents such as
2,4-diaminoquinazolin have been applied in preclinical experiments
and in clinical trials in other cancers [171]. The need to evaluate the
effects of these agents in malignant gliomas is urgent.
Currently, targeting these pathways in GSCs has not yet delivered
convincing results. Destroying glioma vascular niche that is critical for
maintenance of the cluster of cells may be therapeutic [173].
Challenges and Future Directions
The power of molecular targeted therapy (partly shown in Table 1)
has been limited by diverse factors, ranging from complexity of
molecular biology underlying gliomagenesis to challenges of patient
selection to specific therapies, drug delivery, and evaluation of
treatment response. Exploring these factors in great depth might
indicate the appropriate direction for development of molecular
targeted therapy in malignant glioma.
Intricate Biologic Traits in Glioma
Malignant gliomas are known to harbor complex heterogeneity at
the genomic and molecular levels and are driven by intricate signaling
cascades. Recently, co-amplification of multiple RTKs such as EGFR
with PDGFR or MET has been found within individual gliomas
[174], namely, intratumoral heterogeneity. Thus, when treated withEGFR inhibitors, MET and/or PDGFR would maintain activation of
downstream pathways, which is a theoretical mechanism of target
therapy resistance [174]. TCGA has demonstrated three core
pathways, RTK/RAS/PI3K, p53, and RB, which are essential for
development of malignant gliomas, and other undiscovered canonical
pathways cannot be ruled out in gliomagenesis. However, these
pathways are not as simple as vector-to-vector models. Instead, this
model features cross-talk and feedback loops that can significantly
affect therapy outcome [70]. Several studies have found complicated
interplay among PI3K-MAPK-p53-RB pathways, which can com-
pensate for any single pathway perturbation [23]. Moreover, recent
data show that EGFR-VEGF(R) cross-talk exists in both tumor and
tumor-associated endothelial cells and is involved in tumor survival
and angiogenesis in an intracrine fashion [175]. Hence, multiple lines
of evidence suggest that successful targeted therapy should require
designed combinations of inhibitors to block pathway cross-talk and
feedback and suppress upfront and acquired resistance.
Malignant gliomas are also characterized by genomic instability,
which favors gene mutations and chromosomal alterations, and
cytotoxic agents and radiotherapy would accelerate the mutagenesis
[70,176]. Recently, oncogene addiction, whereby tumors depend on
a single oncogenic activity for maintenance of malignant phenotype
and cell survival, has been proposed in gliomas with complex genetic
aberrations. After exposure to therapeutic agents, glioma cells can
escape from one established oncogene addiction to another oncogene,
which may explain the reason why previous drugs cease to be effective
and the tumor acquires drug resistance [177]. Thus, simultaneously
targeting the existing oncogene addiction and oncogene addiction
transition may have feasibility. Another highly significant finding is
that a small subset of GBMs harbors chromosomal translocations that
lead to production of oncogenic fusion proteins demonstrating a
novel mechanism of pathogenicity [178]. For instance,
FGFR3-TACC3 fusion oncogene greatly enhances tumor progression
relative to wild-type FGFR3 and an inhibitor targeting FGFR
prolongs survival of mice harboring intracranial FGFR3-TACC3–
initiated glioma [179]. These results powerfully suggest new
therapeutic approaches for the subset of malignant gliomas.
Biomarkers in Molecular Targeted Therapy
Due to the high heterogeneity of gliomas, each of which may
respond differently to one targeted therapy, there has been
considerable interest in identifying molecular markers of glioma
that predict a response to a particularly molecular targeted therapy,
similar to MGMT status predicting better glioma response to the
alkylating agent TMZ [37]. The goal would be that patients are
parsed into different groups based on the biomarkers that are most
likely to predict benefit from the particular treatment. Originally,
researchers thought that the presence of EGFR overexpression and
EGFR mutations in gliomas could predict activity of EGFR-targeted
drugs in patients with gliomas with these aberrations [180]. However,
this potential treatment approach still has not been clear with
contradictory findings in previous clinical trials (see Growth Factor
Receptors section). Some studies also found that tumors with
EGFRvIII and intact PTEN and tumors with low phosphorylated
Akt levels are more likely to respond to EGFR inhibitors.
Unfortunately, subsequent studies did not confirm these initial
observations [2]. With EGFR amplification or mutation in gliomas
limited in their use as prognostic factors for response to anti-EGFR
therapeutics, a study of in situ analysis found that mutant EGFR
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anti-EGFR treatments, which suggests further investigation of EGFR
mutant dimerization such as EGFRwt-EGFRvIII and EGFR-
vIII-EGFRc958 heterodimers as a potential parameter for predicting
anti-EGFR therapy response [181].
Additionally, previous trials reported that a response to integrin
inhibitors is a function of MGMT expression. However, the result of
the primary endpoint of the phase III trial (NCT00689221) was
reported this year and it did not achieve the expected outcome; newly
diagnosed GBM patients withMGMT gene promoter methylation did
not live significantly longer when treated with cilengitide plus
chemo-radiotherapy (www.merckserono.com). The benefit seen in
patients with promoter methylation of MGMT may possibly remain
correlated to TMZ; thus, MGMT cannot yet be used as a predictive
biomarker for anti-integrin therapy.
As well, there has been no convincing evidence of a correlation
between other molecular alterations in glioma and response to
molecular targeted therapies. Recent data show that mTOR
inhibition may be beneficial in a subpopulation of GBM patients
with high baseline tumor levels of phosphorylated ribosomal protein
p70S6K, which is a downstream activator of mTOR signaling [112].
Moreover, PIK3R1, a newly identified mutation, increases the
likelihood that agents targeting the PI3K pathway would fail [176].
The predictive role of these molecules in treatment response remains
to be elucidated in future clinical trials.
Difficulties in Clinical Trials
The success of molecular targeted therapies in clinical trials may be
also limited by several factors such as drug delivery, pharmacologic
effects, evaluation, and so on.
First, the delivery of agents into the brain is regulated by the BBB
that allows lipophilic agents of small molecules to pass through. The
BBB becomes the obstacle for entrance of large or water-soluble
molecules and limits the ability of drugs to reach sufficient
concentration in glioma tissue. Drug development should focus on
penetration or bypass of the BBB with techniques like convectio-
n-enhanced delivery, liposomal carriers, and nanoscale particles.
Second, when penetrated into the central nervous system, drugs can
cause diverse side effects, despite exhibiting therapeutic activities.
Furthermore, since normal cells and glioma cells share the same
pathways, unacceptable toxicity may derive from the pathway-specific
treatments, which may stifle the therapeutic potential of many potential
agents. Moreover, targeted agents are evaluated in clinical trials similarly
to cytotoxic drugs in phase I trials, whereby the maximum tolerated dose
is assessed. These doses may not be the effective concentration to
significantly affect tumor growth or induce tumor response in phase II
trials. Targeted agents are badly in need of a different type of evaluation.
In addition, attention needs to paid to drug interaction when combined
with cytotoxic drugs, other molecular targeted agents, or enzyme-indu-
cing antiepileptic drugs.
Third, the difficulty in evaluation of response remains an important
component. Radiologic response rate, if low, is a sign of failure inmost trials
of molecular targeted agents. However, a majority of molecular targeted
agents have the ability to inhibit tumor growth but not kill tumor cells. It
may be that evaluation of radiologic response is more suitable for cytotoxic
drugs than molecular targeted agents. In addition, antiangiogenesis
treatment such as bevacizumab rapidly decreases edema and makes
assessment of radiographic response difficult. Thus, redefining the criteriafor evaluation of response of molecular targeted therapy in malignant
glioma is an urgent need.
Opportunities in Other Oncogenic Pathways
Given the limited antitumor activity of current RTK signaling
inhibitors in malignant glioma, novel agents targeting the other two
major oncogenic pathways, the p53/MDM2-MDM4-p14ARF and
RB1/CDK4/p16INK4A/CDKN2B, have increasingly gained atten-
tion. However, it is difficult to design small molecules for these
loss-of-function targets. Several preclinical studies supported that an
inhibitor of CDK4 and CDK6, PD0332991, could efficiently cross
the BBB, suppress the growth of intracranial GBM xenograft tumors,
and significantly prolong survival. RB status, as well as p16INK4a
and CDK4, was a determinant of potential benefit from the therapy
[182,183]. This area remains a great untapped potential strategy.
Recently, metabolic pathways have gained attention as high
frequencies of isocitrate dehydrogenase 1 (IDH1)/IDH2 mutation
have been found in secondary GBMs and low-grade gliomas [21].
Mutant IDH inhibits wild-type IDH activity, impairs affinity for its
substrate, catalyzes the nicotinamide adenine dinucleotide phosphate
(NADPH)-dependent reduction of α-ketoglutarate to D-2-hyroxyglu-
tarate, and acquires oncogenic activity possibly through induction of
hypoxia induced factor-1α pathway and formation of 2-hyroxyglutarate
[184]. This altered tumor metabolic pathway offers the possibility of
molecularly targeted therapeutic intervention; however, there still exist
difficulties and controversies regarding the largely unknown mecha-
nisms underlying the oncogenic effects of IDHmutations.More studies
are warranted to achieve the therapeutic purpose.Combination of Molecular Targeted Therapy with Other
Therapeutic Modalities
Redundancy and complexity of signaling pathways in malignant
glioma often lead to failure even with combined molecularly targeted
agents. Therefore, adding other therapeutic modalities to molecular
targeted therapy may create new avenues for success.
Previous clinical trials of immunotherapy in malignant glioma have
reported induction of systemic immune responses and met with
success in prolonging survival [185,186]. Another discovery that
mTOR playing a pivotal role in RTK/RAS/PI3K signaling pathway
activation may also be a critical regulator of the immune response
presents an opportunity to combine molecular targeted therapies and
immunotherapeutic approaches with very promising potential [70].
Recent studies have also demonstrated thatmicroRNAs (miRNAs), a
class of novel small non-coding RNA molecules, are involved in critical
signaling pathways inmalignant glioma and present potentially effective
therapeutic targets [187]. Regulation of aberrant miRNA could affect
sensitivities to molecular targeted therapy [188]. Therefore, combina-
tion ofmiRNA-based therapy withmolecular targeted therapymight be
able to exert a synergistic effect for treatment of malignant gliomas,
particularly for molecular targeted agent–resistant patients.
Finally, global gene expression analysis incorporated into patient
glioma analysis and treatment management may identify predicative
and therapeutic biomarkers, stratify patients based on molecular
characteristics, and provide individualized therapies. Additionally,
development in the investigation of novel molecular targeted agents
and multiple combined therapies may allow the “molecularly tailored”
therapeutic strategies to cure malignant gliomas in the future.
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